Russian biopharmaceutical company PSK Pharma has announced the launch of a next-generation incretin-based injectable therapy, Tirzero® Slim, containing tirzepatide as the active ingredient. The product belongs to the class of dual GIP/GLP-1 receptor agonists, currently considered one of the most advanced approaches to the management of type 2 diabetes and obesity.
As part of the international SURPASS clinical program, which included more than 1,500 patients of different ages and genders with type 2 diabetes, tirzepatide demonstrated reductions in glycated hemoglobin (HbA1c) levels and significant efficacy in weight reduction (source).
Evgenia Shapiro, General Director of PSK Pharma, commented:
«Today, PSK Pharma has extensive in-house expertise in working with modern peptide-based therapies such as semaglutide and its alternatives. Tirzepatide represents a logical continuation of our long-standing efforts in developing effective treatments for type 2 diabetes and weight management. Diabetes and obesity remain among the most serious chronic diseases worldwide. According to the International Diabetes Federation, more than 589 million people aged 20 to 79 are currently living with diabetes. Tirzero® Slim is PSK Pharma’s investment in expanding access to innovative metabolic therapies for patients. Our annual production capacity exceeds 3 million packs».
Tirzero® Slim is intended for use in adults aged 18 and older and is administered subcutaneously once weekly. It is supplied as a reliable pre-filled pen injector with four needles. This method of administration has already proven effective in other PSK Pharma weight management products. The product is available in the following dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per dose.
Tirzero® Slim is indicated for the treatment of adults with inadequately controlled type 2 diabetes as an adjunct to diet and exercise. It is also recommended for weight management as an adjunct to a low-calorie diet and increased physical activity.